



Zelda Therapeutics Ltd

ACN 103 782 378

www.zeldatherapeutics.com

Level 45

108 St Georges Terrace,
Perth Western Australia 6000

05 December 2016

ZELDA THERAPEUTICS ENTERS INTO COLLABORATION AGREEMENT WITH PRESTIGIOUS TELETHON KIDS INSTITUTE

HIGHLIGHTS

- Zelda to work with one of Australia's leading medical research institutes, the Telethon Kids Institute
- Expands pre-clinical research programme from breast cancer to now include paediatric brain cancers
- Rigorous series of experiments to generate high quality data pack
- Follows on from recently announced positive results from Zelda's pre-clinical breast cancer research being conducted in Spain
- Data expected during 2017

Zelda Therapeutics Ltd (ASX: ZLD, "Zelda" or the Company) is pleased to announce that it has entered into a collaboration agreement with the highly regarded, Perth-based Telethon Kids Institute (www.telethonkids.org.au). This collaboration will initially focus on pre-clinical testing of Zelda's compounds, formulations and protocols in the area of children's brain cancer.

The collaboration with the Telethon Kids Institute will be confined to pre-clinical research accessing the Institute's validated cell and animal models for the studies. Through the research, the Institute will examine the potential for Zelda's compounds to act as anti-cancer agents, either alone or in combination with existing treatments. The initial studies are due to commence in early 2017 with results expected later in the year.

The research consists of a series of experiments that have been designed within stringent scientific protocols to produce a comprehensive data pack that can be used as the basis for any future clinical trials either in Australia or in other geographies.

The collaboration and studies, build on the Company's pre-clinical research activities at Complutense University Madrid with renowned researchers Professor Manuel Guzmán and Professor Cristina Sánchez who are both considered the leaders in the research of anti-cancer effects of cannabinoids.

The new collaboration with the Telethon Kids Institute demonstrates the Company's strong momentum towards conducting rigorous pre-clinical and clinical studies aimed at validating the anecdotal patient responses to medical cannabis observed to date, to produce industry-standard data packs and trial data.

For personal use only

Zelda intends on sourcing the cannabinoid research material via a supply agreement with AusCann Group Holdings Ltd. AusCann has a partnership with the world's largest medical cannabis cultivator and processor - Canadian group Canopy Growth Corporation. Subject to AusCann securing the appropriate import permits, and Canopy securing an export permit, this material will be sourced from Canada and supplied to the Telethon Kids Institute for the approved research purposes. These research activities fall within the recently passed Australian Narcotics Drug Amendment Act and re-scheduling of cannabis from Schedule 9 (prohibited substance) to Schedule 8 (controlled drug) under the Poisons Standard.

Executive Chairman Harry Karelis stated:

"Zelda was established to conduct a series of pre-clinical and clinical activities to determine whether positive anecdotal experiences observed in patients in California can be reproduced in a controlled laboratory and clinical setting. We are excited to be partnering with the Telethon Kids Institute in the important area of childhood cancer. Positive results from these studies have the potential to lay the foundations for improved treatment outcomes and quality of life for cancer patients."

CONTACTS

Corporate

Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Media

Andrew Ramadge
Media & Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (*Aunt Zelda's*) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols. Zelda will use this information to design a series of human clinical trials that have a high probability of success given the existing patient data and experiences it has access to.

In addition, Zelda has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry.

About Telethon Kids Institute (telethonkids.org.au)

Telethon Kids Institute is one of the largest, and most successful medical research institutes in Australia, comprising a dedicated and diverse team of more than 500 staff and students. Established in 1990 by Founding Director and former Australian of the Year Professor Fiona Stanley, the Institute was among the first to adopt a multidisciplinary approach to major health issues.